BBIO — BridgeBio Pharma Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousLarge CapMomentum Trap

Annual cashflow statement for BridgeBio Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-505	-586	-485	-653	-543
Depreciation
Non-Cash Items	90.8	83.7	24	114	-15.5
Unusual Items
Purchased R&D
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	14.9	-1.06	34.3	5.06	32
Change in Accounts Receivable
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities	-400	-498	-419	-528	-521
Capital Expenditures	-7.52	-13.2	-6.32	-1.31	-8.91
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-45.5	-188	459	55.3	69.7
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-53	-201	453	54	60.8
Financing Cash Flow Items	-41.9	-164	-0.724	-7.68	-7.53
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	447	736	-13.1	452	748
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-5.52	37.7	20.5	-22.2	289